Skip to main content

Advertisement

Analyse d’articles — avec la collaboration de la Société Francophone de Médecine Sexuelle (SFMS)

Review of publications — with the collaboration of the Société Francophone de Médecine Sexuelle (French-speaking Society for Sexual Medicine)

Article metrics

  • 464 Accesses

Références

  1. 1.

    Marks LS, Mazer NA, Mostaghel E, et al (2006) Effect of testosterone replacement therapy on prostate tissuein men with late-onset hypogonadism: a randomized controlled trial. JAMA 296:2351–32361

  2. 2.

    Morgentaler A (2009) Testosterone therapy in men with prostate cancer: ethical and scientific considerations. J Urol 81:972–979

  3. 3.

    Kaufman JM, Graydon RJ (2004) Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 172:920–922

  4. 4.

    Agarwal PK, Oefelein MG (2005) Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 173:533–536

  5. 5.

    Khera M, Grober ED, Najari B, et al (2009) Testosterone replacement therapy following radical prostatectomy. J Sex Med 6: 1165–1170

  6. 6.

    Sarosdy MF (2007) Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 109:536–541

  7. 7.

    Endogenous Hormones and Prostate cancer Collaborative Group (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170–178

  8. 8.

    Page ST, Lin DW, Mostaghel EA, et al (2006) Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91:3850–3856

  9. 9.

    Klotz L, Zhang L, Lam A, et al (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131

Références

  1. 1.

    Laurent S, Cockcroft J, Van Bortel L, et al (2006) European network for non-invasive investigation of large arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588–2605

  2. 2.

    Mancia G, DeBacker G, Dominiczak A, et al (2007) Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105–1187

  3. 3.

    Gurovich AN, Beck DT, Braith RW (2009) Aortic pulse wave analysis is not a surrogate for central arterial pulse wave velocity. Exp Biol Med 234:1339–1344

  4. 4.

    Vlachopoulos C, Aznaouridis K, Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 55:1318–1327

  5. 5.

    Kita T, Kitamura K, Hashida S, et al (2003) Plasma adrenomedullin is closely correlated with pulse wave velocity in middle-aged and elderly patients. Hypertens Res 26:887–893

  6. 6.

    Levy D, Hwang SJ, Kayalar A, et al (2007) Associations of plasma natriuretic peptide, adrenomedullin, and homocysteine levels with alterations in arterial stiffness: the Framingham Heart Study. Circulation 115:3079–3085

Download references

Author information

Correspondence to J. Buvat.

Rights and permissions

Reprints and Permissions

About this article